LONG-ACTING TECHNOLOGIES FOR HCV, TB, AND MALARIA TREATMENT
In September 2021, the Medicines Patent Pool (MPP) announced a licence agreement with Tandem Nano Ltd. for University of Liverpool’s Unitaid-funded project LONGEVITY long-acting technologies, which, if proven safe and effective could help achieve optimal dosing regimens for malaria chemoprophylaxis, tuberculosis prevention, and hepatitis C cure.
The agreement allows sublicensees worldwide to develop finished products anywhere in the world, and to sell or distribute the resulting medicines for administration to patients in all low- and middle-income countries, on a royalty-free basis.
|Prevention and/or treatment of HIV
|Eligibility for sublicences
|Sublicences can be issued to any qualified entity in any country of the world (for development and/or commercialisation)
|Allows manufacturing worldwide
|Geographical scope for sale
|Allows for sale in all LMICs. The licence contains a requirement of Affordable Price
|Sales outside the licensed territory
|Allowed if country issues compulsory license, or where the activity does not infringe a licensed patent granted and in force or rely upon licensed know-how
|Sublicences are royalty-free for all supplies to LMICs, in both public and private markets
|Products will comply with the following standards: WHO Prequalification Programme (PQ), Global Fund/ Unitaid Expert Review Panel (ERP), US FDA and/or another WHO Listed Regulatory Authority as agreed between MPP & sublicensee
|MPP sublicensee will not seek and will waive, regulatory exclusivity in LMICs in relation to any data relating to licensed products.
|Obligation for licensor to list licensed patents, also for improvements of LA.
A right to maintain and enforce them remains with licensor.
|Until last licensed patent has expired, lapsed or has been invalidated
|Royalty-free, non-exclusive and sub-licensable licence over any Improvement